




RealRate

PHARMACEUTICAL 2022

Brooklyn ImmunoTherapeutics Inc.
Rank 470 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

Brooklyn ImmunoTherapeutics Inc. Rank 470 of 475



The relative strengths and weaknesses of Brooklyn ImmunoTherapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Brooklyn ImmunoTherapeutics Inc. compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 292% points. The greatest weakness of Brooklyn ImmunoTherapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 1,189% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,677%, being 1,401% points below the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	18,766
Cost of Goods Sold	0
Intangible Assets	2,044
Liabilities, Current	3,677
Liabilities, Non-Current	2,320
Other Assets	10,949
Other Compr. Net Income	0
Other Expenses	86,128
Other Liabilities	19,930
Other Net Income	-8,749
Property and Equipment	670
Research and Development	12,705
Revenues	0
Selling, General and Administrative Expense	14,724

Output Variable	Value in 1000 USD
Assets	32,429
Liabilities	25,927
Expenses	113,557
Stockholders Equity	6,502
Net Income	-122,306
Comprehensive Net Income	-122,306
Economic Capital Ratio	-1,677%

